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Meta-analyses suggest that the serotonin transporter linked polymorphic region (5-
HTTLPR) short (S) allele, relative to the long (L) allele, is associated with risk for alcohol
dependence, particularly among individuals with early onset antisocial alcoholism.Youth in
substance use treatment tend to show antisocial or externalizing behaviors, such as con-
duct problems, which predict worse treatment outcome. This study examined a pathway
in which 5-HTTLPR genotype is associated with externalizing behavior, and the interme-
diate phenotype of externalizing behavior serves as a link between 5-HTTLPR genotype
and substance use treatment outcome in youth. Adolescents (n= 142) who were recruited
from addictions treatment were genotyped for 5-HTTLPR polymorphisms (S and LG carri-
ers vs. LALA), assessed for externalizing and internalizing behaviors shortly after starting
treatment, and followed over 6-months. 5-HTTLPR genotype was not associated with
internalizing behaviors, and was not directly associated with 6-month substance use out-
comes. However, 5-HTTLPR genotype was associated with externalizing behaviors (S and
LG>LALA), and externalizing behaviors predicted alcohol and marijuana problem severity
at 6-month follow-up. Results indicated an indirect (p<0.05) and non-specific (i.e., both
alcohol and marijuana severity) effect of 5-HTTLPR genotype on youth substance use treat-
ment outcomes, with externalizing behaviors as an important linking factor. Adolescents
in substance use treatment with low expressing (S and LG) 5-HTTLPR alleles and exter-
nalizing behavior might benefit from intervention that addresses serotonergic functioning,
externalizing behaviors, and substance use to improve outcomes.
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INTRODUCTION
Serotonergic functioning has been associated with externalizing
behaviors, such as conduct problems and aggression; internaliz-
ing behaviors, such as depression and anxiety (1); and substance
use (2). Externalizing behaviors commonly precede and predict
adolescent substance use (3). Internalizing behaviors also have
been linked with youth substance use, under certain conditions
(4). In adolescents, serotonin transporter genotype may be more
strongly associated with intermediate phenotypes of externalizing
and internalizing behaviors, than with a substance use pheno-
type, because the intermediate phenotypes often manifest prior to
substance use behavior. Among adolescents in substance use treat-
ment, externalizing behaviors robustly predict worse outcomes
(5). Based on these observations, this study of adolescent substance
users tested a pathway in which serotonin transporter genotype is
associated with externalizing and internalizing behaviors as inter-
mediate phenotypes, and the intermediate phenotypes provide a
link between serotonin transporter genotype and substance use
treatment outcomes. Increased understanding of how a genetic
marker is associated with treatment outcome could ultimately help
to guide the development of personalized interventions (6).
Serotonergic functioning involves SLC6A4, a gene in the reg-
ulatory pathway for serotonin (5-HT), which encodes the 5-HT
transporter (5-HTT) protein. The SLC6A4 gene has a functional
polymorphism in its regulatory region,known as the 5-HTT linked
promoter region (5-HTTLPR), which has two allele variants: a 44-
bp insertion [long (L) allele] or deletion [short (S) allele]. The
S-allele is associated with a 2- to 2.5-fold decrease in 5-HTT tran-
scription rate compared to the L-allele (7). The L-allele can be
further characterized by the presence of an adenine to guanine
(A>G) change (8, 9). The L-allele with guanine (LG) and the S-
allele have similar transcriptional activity, whereas the L-allele with
adenine (LA) is associated with increased transcriptional activity
(10). Based on the functionality of alleles (10), studies have com-
pared“low” vs. “high” expressing allele carriers (i.e., LALA vs. S and
LG carriers) (11, 12).
The 5-HTTLPR short, relative to the long, allele has been asso-
ciated with risk for both externalizing and internalizing behaviors
(1, 13). Although most studies report that the 5-HTTLPR S-allele
increased risk for externalizing behaviors [e.g., Ref. (14–16)], one
study reported no association with conduct problems (17). In
adolescents, 5-HTTLPR S-allele played a role in the association
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between internalizing behaviors and alcohol use, possibly through
shared risk factors, such as stress reactivity [e.g., Ref. (4)]. There is
stronger evidence of an association between serotonin transporter
genotype and externalizing, than internalizing, behaviors. Mixed
findings for externalizing behaviors may be due, in part, to the
need to account for high vs. low expressing 5-HTTLPR L-allele
subtypes (LA and LG).
With regard to substance use, the S-allele was associated with
slightly increased odds of alcohol dependence in two meta-
analyses (18, 19). Importantly, the S-allele was more common
among individuals with an early onset, severe form of alcoholism
associated with antisocial features (18). Further, a study of adoles-
cents found that the S-allele was associated with the early devel-
opment of alcohol use [e.g., Ref. (20)]. These findings suggest that
the association between 5-HTTLPR genotype and alcohol involve-
ment may occur through a pathway that involves externalizing
behavior as an intermediate phenotype (1, 16, 21).
Few studies have examined 5-HTTLPR genotype in relation to
substance use treatment outcome. In a study of African Amer-
ican cocaine and alcohol abusers, S-allele homozygotes showed
less improvement on drinking measures at 6-month follow-up
(22). Another study found that the 5-HTTLPR S-allele was asso-
ciated with relapse to alcohol over 3-month follow-up among
Caucasian males treated for alcohol dependence (23). The study
of treated alcohol dependent males discussed the possibility that
the 5-HTTLPR S-allele does not directly influence substance use
relapse, but may have effects on outcome through an intermediate
phenotype involving impaired behavioral control, as manifested
by externalizing behaviors. No study has examined whether 5-
HTTLPR genotype has an indirect effect on treatment outcome
through intermediate phenotypes of externalizing or internalizing
behaviors.
This study addresses gaps in knowledge regarding 5-HTTLPR
genotype as a predictor of adolescent substance use treatment
outcome. We hypothesized, as suggested by research with treated
adults (23), that 5-HTTLPR genotype would be indirectly associ-
ated with adolescent posttreatment alcohol and marijuana prob-
lem severity through the intermediate phenotype of externalizing
behavior. Specifically, S/LG allele carriers, relative to LA homozy-
gotes, were predicted to report greater externalizing behavior [see
Ref. (24)], and greater externalizing behavior was predicted to be
associated with greater alcohol and marijuana problem severity at
6-month follow-up [see Ref. (5)] (see Figure 1).
MATERIALS AND METHODS
PARTICIPANTS
In the United States, 6.1% of youth (ages 12–17) met criteria for a
DSM-IV alcohol or illicit drug use disorder in the past year (25).
The prevalence of past year substance use disorder in the urban
setting of Pittsburgh, PA, USA is similar to national prevalence
rates (26). This study recruited 209 adolescents (ages 14–18) from
community-based substance use treatment in Pittsburgh. Of the
209 youth, 153 (73.2%) youth were successfully genotyped (n= 55
did not provide DNA, n= 1 sample could not be genotyped).
Cases with missing data due to incomplete baseline questionnaires
(n= 11) were excluded, resulting in a baseline analysis sample of
142 adolescents. Youth who were vs. were not included in the
FIGURE 1 | Hypothesized mediation (indirect effects) model that was
tested. C′ represents the direct effect of independent variable (5-HTTLPR
genotype: high vs. low expressing) on the dependent variable (alcohol and
marijuana problem severity at 6 months) after controlling for the intervening
variable (externalizing behavior). The C path (not labeled in the figure)
represents the total effect of the independent variable on the dependent
variable. Covariates: gender, age, race (Caucasian vs. all other ethnicity),
socio-economic status, and baseline frequency of substance use.
analysis sample did not differ (p> 0.10) on demographic charac-
teristics (age, gender, race, and SES) or frequency of using alcohol
or marijuana at baseline.
The analysis sample was 66.2% male. Based on self-reported
race/ethnic identity, the sample was 86.6% Caucasian, 7.0%
African American, and 6.3% other ethnicity (e.g., bi-racial). Aver-
age age was 16.7 (SD= 1.2). Sample demographic characteristics
(Table 1) were similar to those of youth admitted to publicly
funded substance use treatment (27). Participants were, on aver-
age, middle-class in socio-economic status [mean= 2.4, SD= 1.1;
range= 1–5; (28)]. Most (85.9%) had a current (past 6 months)
DSM-IV cannabis use disorder, and almost half (47.2%) had a cur-
rent DSM-IV alcohol use disorder. Six-month follow-up data were
available for 89% (n= 126) of the sample; those who did vs. those
who did not complete follow-up did not differ on demographics,
internalizing or externalizing symptoms, and baseline alcohol or
marijuana problem severity (p> 0.15).
PROCEDURE
Youth admitted to community-based intensive outpatient sub-
stance use treatment were approached to participate in a longi-
tudinal study on treatment outcome (29, 30). Treatment involved
three 3-h group sessions per week for 6–8 weeks, with content
that supported a goal of abstinence from alcohol and illicit drugs.
Informed consent (from 18 years olds) or assent (from minors,
with informed consent for the minor’s participation provided by
the minor’s parent) was obtained prior to initiating study pro-
cedures. The baseline assessment, which was typically completed
within 2 weeks of treatment entry, collected substance use and
psychiatric data. The same domains were assessed at follow-up.
Baseline data were collected from 2004 to 2009. Highly trained
research associates collected interview data with high reliability
(31),and saliva DNA according to protocol.Youth completed ques-
tionnaires at home, which were returned at the interview session or
by mail. The University of Pittsburgh’s Institutional Review Board
approved the study protocol (no. IRB0402001).
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Table 1 | Descriptive statistics for the total sample, and high vs. low expressing allele groups.
Total High exp Low exp
Demographics n % n % n %
Female 48 33.8 11 31.4 37 34.6
Male 94 66.2 24 68.6 70 65.4
Ethnicity
Caucasian 123 86.6 28 80.0 95 88.8
African American 10 7.0 3 8.6 7 6.5
Multi-racial 9 6.3 4 11.4 5 4.7
Baseline Mean (SD) Mean (SD) Mean (SD)
Age 16.7 (1.2) 16.7 (1.2) 16.7 (1.2)
Socio-economic status (28) 2.5 (1.1) 2.5 (1.2) 2.5 (1.1)
Externalizing composite T score 62.1 (13.4) 57.2 (13.5) 63.7 (13.0)
Internalizing composite T score 52.1 (13.4) 49.1 (14.6) 53.2 (12.9)
Frequency of substance use (past 6-months)a
Alcohol use 3.6 (1.9) 3.3 (1.9) 3.7 (1.9)
Marijuana use 5.6 (2.5) 5.6 (2.8) 5.7 (2.3)
n % n % n %
Current DSM-IV alcohol use disorder 67 47.2 13 37.1 54 50.5
Alcohol abuse 54 38.0 11 31.4 43 40.2
Alcohol dependence 13 9.2 2 5.7 11 10.3
Current DSM-IV cannabis use disorder 122 85.9 27 77.1 95 88.8
Cannabis abuse 73 51.4 20 57.1 53 49.5
Cannabis dependence 49 34.5 7 20.0 42 39.3
Current DSM-IV psychopathology
Conduct disorder 53 37.3 13 37.1 40 37.4
Attention deficit hyperactivity disorder 50 35.2 7 20.0 43 40.2
Major depression 20 14.1 7 20.0 13 12.1
6-month Follow-up (time frame: past 6months) Mean (SD) Mean (SD) Mean (SD)
Frequency of substance usea
Alcohol use 2.9 (1.8) 2.4 (1.8) 3.0 (1.9)
Marijuana use 3.6 (2.7) 2.9 (2.4) 3.8 (2.8)
Rutgers alcohol problems index score 7.9 (10.3) 8.6 (11.5) 10.1 (12.2)
Rutgers marijuana problems index score 11.1 (13.4) 8.5 (11.3) 14.8 (16.4)
Baseline N=142; 6-month n=126; high exp, high expressing (LALA, n=35); low exp, low expressing (S and LG, n=107); BL, baseline; SD, standard deviation; current,
past 6 months.
aFrequency coded: 0=never used, 1=no use in the last 6 months, 2=used<once per month, 3=used once per month, 4=used 2–3 times per month, 5= used
once per week, 6=used 2–3 times per week, 7=used 4–6 times per week, and 8=daily use.
DNA COLLECTION AND GENOTYPING
DNA from saliva was collected using a mouthwash protocol (32).
Samples were subjected to whole genome amplification using
multiple displacement amplification (33), quantified by the pico
green protocol, and diluted to 40 ng/µl for storage. A polymerase
chain reaction protocol followed by double restriction endonu-
clease digestion was used to identify the 5-HTTLPR (SLC6A4)
and rs25531 variants: S, LA, and LG (9). The primer sequences
were: (forward) 5′-TCCTCCGCTTTGGCGCCTCTTCC-3′, and
(reverse) 5′-TGGGGGTTGCAGGGGAGATCCTG-3′. The L-allele
was subtyped for rs25531. The A>G SNP of rs25531 was concur-
rently detected by digesting the amplified fragments with MspI
(New England Biolabs, Beverly, MA, USA), where the A>G sub-
stitution creates an additional MspI site. Amplification products
were simultaneously resolved by electrophoresis on 3.5% agarose
gels.
The genotype distribution in the total sample (N = 142)
was: SS, n= 19 (13.4%); SLG, n= 9 (6.3%); LGLG, n= 2
(1.4%); SLA, n= 60 (42.3%); LGLA, n= 17 (12.0%); and LALA,
n= 35 (24.6%). SS, SL, and LL frequencies did not deviate
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significantly from Hardy–Weinberg equilibrium in the total sam-
ple (χ2[df= 1]= 0.17), or in the Caucasian subsample1 (N = 123:
SS n= 18, SL n= 65, LL n= 40; χ2[df= 1]= 1.04). As in prior
studies [see Ref. (8)], “low” expressing S and LG alleles were
grouped together and compared with “high” expressing LA allele
(total sample: LALA n= 35 vs. all other types n= 107; Caucasian:
LALA n= 28 vs. all other types n= 95).
MEASURES OF SUBSTANCE INVOLVEMENT AND PSYCHOPATHOLOGY
An adapted structured clinical interview for DSM-IV SUDs [SCID;
(34)] assessed past 6-month SUD diagnoses at baseline and follow-
up. The adapted SCID has acceptable reliability and validity (31).
The Kiddie-schedule for affective disorders and schizophrenia (35)
assessed current DSM-IV psychopathology.
The youth self-report (YSR; ages 14–17, 112 items) or young
adult self-report (YASR; age 18, 116 items) (36, 37) was completed
at baseline. Items used a 6-month time frame, with responses
coded as“not true,”“sometimes true,”or“often true.”A normalized
T score was computed for the internalizing (withdrawn, somatic
complaints, and anxious/depressed subscales) and externalizing
(delinquent behavior and aggressive behavior subscales) compos-
ite indices. The externalizing composite score includes items on
substance use (e.g., “I use drugs for non-medicinal purposes”).
The drug consumption questionnaire assessed frequency of
alcohol and marijuana use in the past 6 months at each assess-
ment using a 9-point scale (0= never used, 1= no use in the last
6 months, 2= used less than once per month, 3= used once per
month, 4= used 2–3 times per month, 5= used once per week,
6= used 2–3 times per week, 7= used 4–6 times per week, and
8= daily). The substance use frequency items have satisfactory
reliability and validity (31).
The Rutgers alcohol problem index [RAPI; (38)] and Rutgers
marijuana problem index [RMPI; (39)], which each include 18
items rated on a 0–4 scale (0= 0 times, 1= 1–2 times, 2= 3–
5 times, 3= 6–10 times, and 4≥ 10 times), assessed alcohol
and marijuana problem severity at 6-month follow-up (RAPI
alpha= 0.91; RMPI alpha= 0.92). RAPI and RMPI scores were
positively correlated (r = 0.67, p= 0.001).
DATA ANALYSIS
Bivariate correlations were run as a preliminary step to deter-
mine the utility of testing hypothesized mediation (indirect)
effect models (40). Tests for indirect effect used a bootstrapping
procedure (5,000 resamples) available as an SPSS macro (41).
Each model (see Figure 1; Table 2) tested an “A path,” which
represents the path from the independent variable (serotonin
transporter genotype) to the intervening variable (e.g., exter-
nalizing score); a “B path,” which represents the direct effect of
the intervening variable (e.g., externalizing score) on the depen-
dent variable (baseline RAPI/RMPI score); a “C path,” which
represents the total effect of the independent variable on the
dependent variable; and a “C′ path,” which represents the direct
effect of the independent variable on the dependent variable,
1The genotype distribution in the Caucasian sample (N = 123) was: SS, n= 18
(14.6%); SLG, n= 9 (7.3%); LGLG, n= 2 (1.6%); SLA, n= 56 (45.5%); LGLA, n= 10
(8.1%); and LALA, n= 28 (22.8%).
Table 2 | Parameter estimates for models, testing indirect effects of
externalizing symptoms on the association between serotonin
transporter genotype (A/G) and 6-month RAPI and RMPI score.
B SE t p
OUTCOME: 6-month RAPI
A path 6.69 2.60 2.57 0.011
B path 0.24 0.07 3.46 0.001
C path 1.33 2.07 0.64 0.523
C′ path −0.29 2.03 −0.14 0.885
Covariates: gender 3.28 1.83 1.79 0.076
Age −0.34 0.73 −0.46 0.642
Race 0.06 2.69 0.02 0.983
SES 1.35 0.81 1.66 0.098
BL alcohol days 1.48 0.46 3.21 0.002
Indirect effect point estimate=1.62 (BCa 95% CI: 0.36, 3.84).
Model summary: n=125; R2=0.19, F (7, 117)=4.03, p=0.0005.
OUTCOME: 6-month RMPI
A path 6.44 2.66 2.42 0.017
B path 0.28 0.09 3.09 0.002
C path 4.88 2.71 1.80 0.075
C′ path 3.05 2.68 1.13 0.259
Covariates: gender 6.07 2.46 2.47 0.015
Age 0.09 0.94 0.10 0.922
Race 1.86 3.46 0.54 0.592
SES 1.35 1.05 1.28 0.202
BL marijuana days 1.20 0.46 2.58 0.011
Indirect effect point estimate=1.83 (BCa 95% CI: 0.39, 4.17).
Model summary: n=122; R2=0.20, F (7, 114)=4.18, p=0.0004.
BL, baseline; 6-mo, 6-month follow-up; RAPI, Rutgers alcohol problems inven-
tory; RMPI, Rutgers marijuana problems inventory; alcohol/marijuana days, num-
ber of use days in the month prior to BL; B, unstandardized coefficient; SE,
standard error; gender (0= female, 1=male); race (0=other race/ethnicity,
1=Caucasian); SES, socio-economic status (1–5, 1= high SES). A path, inde-
pendent variable (serotonin transporter genotype: 0=LALA, 1=S/LG carrier) to
intervening variable (externalizing score); B path, direct effect of intervening vari-
able (externalizing score) on dependent variable (6-month RAPI/RMPI score); C
path, total effect of independent variable on dependent variable; C′ path, direct
effect of independent variable on dependent variable, after controlling for the
intervening variable. Covariates: partial effect of covariates on dependent variable.
after controlling for the intervening variable. A significant indi-
rect effect in the regression model is indicated when the 95%
bias-corrected and accelerated (BCa) confidence interval around
the unstandardized coefficient does not include 0 (41). An indi-
rect effect can be detected in the absence of a significant direct
effect [e.g., Ref. (40, 42)]. Regression analyses controlled for gen-
der, age, race (i.e., Caucasian vs. other race), socio-economic
status, and baseline substance use. There was no difference in
the pattern of results using transformed and untransformed vari-
ables, so results using untransformed data are reported [see Ref.
(43)]. Because 5-HTTLPR allele frequencies differ across race
(44), we conducted secondary analyses only in the Caucasian
subsample.
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RESULTS
COMPARISON OF HIGH vs. LOW EXPRESSING ALLELE GROUPS
In the total sample (see Table 1 for descriptives), 5-HTTLPR geno-
type (0= LALA, 1= S or LG allele carrier) was not associated with
a current DSM-IV alcohol, marijuana, major depression, or con-
duct disorder diagnosis at baseline (p= 0.17, 0.09, 0.25, and 0.98,
respectively). However, the low, compared to high, expressing allele
group was more likely to have current DSM-IV ADHD at baseline
(χ2= 4.71, df= 1, p< 0.05; also observed in only the Caucasian
subsample: χ2= 5.06, df= 1, p< 0.05). High vs. low express-
ing genotype did not differ on internalizing score (p> 0.10),
or frequency of alcohol use (at baseline p> 0.20 or 6-month
follow-up p> 0.10) and marijuana use (at baseline p> 0.75 or
6-month follow-up p> 0.09). However, the high, relative to low,
expressing genotype had a higher externalizing score (t =−2.56,
df= 140, p= 0.01; also observed in only the Caucasian subsample:
t =−2.33, df= 121, p= 0.02).
TESTING AN INDIRECT PATHWAY LINKING 5-HTTLPR GENOTYPE AND
TREATMENT OUTCOME
Preliminary bivariate correlations supported a possible media-
tion (“indirect”) pathway involving an association between 5-
HTTLPR low vs. high expressing genotype and externalizing
behavior (r = 0.21, p= 0.01), and externalizing behavior with 6-
month alcohol and marijuana-related problems (RAPI r = 0.30,
p< 0.01; RMPI= 0.27, p< 0.01). These correlations held in the
Caucasian subsample (p< 0.05). Thus, indirect effect analyses
focus on the association between 5-HTTLPR genotype, exter-
nalizing behavior, and 6-month RAPI and RMPI scores (see
Figure 1).
In predicting 6-month RAPI score (Table 2), 5-HTTLPR
genotype was associated with externalizing behavior (B= 6.69,
p= 0.01; low expressing group was associated with greater exter-
nalizing behavior), and externalizing behavior was positively
associated with 6-month RAPI score (B= 0.24, p= 0.001). 5-
HTTLPR genotype was not directly associated with 6-month
RAPI (B= 1.33, p= 0.52). A significant indirect effect linking
5-HTTLPR genotype to 6-month RAPI scores through exter-
nalizing behavior, adjusting for covariates, was observed: point
estimate= 1.62 (BCa 95% CI: 0.36, 3.84).
For the model predicting 6-month RMPI score, the low express-
ing group was associated with greater externalizing behavior
(B= 6.44, p= 0.02), and externalizing behavior was positively
associated with 6-month RMPI score (B= 0.28, p= 0.002). 5-
HTTLPR genotype was not directly associated with 6-month
RMPI (B= 4.88, p= 0.08). An indirect effect of externalizing
behavior in the association between 5-HTTLPR genotype and 6-
month RMPI score was observed: point estimate= 1.83 (BCa 95%
CI: 0.39, 4.17).
Analyses of the Caucasian subsample, adjusting for covariates,
yielded similar results regarding indirect effects of externalizing
behavior score in the association between 5-HTTLPR genotype
and 6-month RAPI and RMPI scores: RAPI point estimate= 1.66
(BCa 95% CI: 0.34, 4.25); RMPI point estimate= 1.98 (BCa 95%
CI: 0.39, 4.79).
DISCUSSION
Results supported the hypothesis that low, relative to high,
expressing 5-HTTLPR genotype would be associated with greater
externalizing behavior among youth in substance use treatment.
Further, 5-HTTLPR genotype was associated with treatment out-
come only indirectly, through externalizing behavior. These results
are applicable mainly to Caucasian youth in substance use treat-
ment. The finding that the direct association between 5-HTTLPR
genotype and 6-month alcohol and marijuana problem severity
was not significant, suggests that externalizing behaviors provide
an important link in the pathway between 5-HTTLPR genotype
and 6-month substance use treatment outcome in this adolescent
sample.
The association between 5-HTTLPR genotype and external-
izing behaviors in an adolescent treatment sample is consistent
with the stronger association between low expressing 5-HTTLPR
genotype and alcoholism among adults with early onset, antiso-
cial alcoholism (i.e., type II) (18), and with externalizing behaviors
more generally (45). In this adolescent sample, the stronger asso-
ciation between 5-HTTLPR genotype and externalizing behavior,
relative to a substance use phenotype (e.g., DSM-IV alcohol use
disorder), may reflect that the sample has not passed through
young adulthood, a period of high risk for the onset of substance
use disorder.
The absence of an association between 5-HTTLPR genotype
and internalizing behaviors in this study may reflect the relatively
low prevalence of mood and anxiety disorders in this sample. Fur-
ther, the association of ADHD with low expressing alleles observed
in this study differs from other work, which reported associations
between the L-allele and ADHD [e.g., Ref. (46)]. The disparate
findings obtained in this study relative to prior research might
be explained, for example, by specific patterns of co-occurring
psychopathology in a given sample, interactions among genes
(e.g., epistasis) and haplotypes [e.g., Ref. (47)], and effects of
environmental conditions that were not examined.
Results are generally consistent with adult treatment studies,
which found that the 5-HTTLPR S-allele was directly associated
with worse outcome (22, 23). The current study provides a unique
contribution in finding that low expressing 5-HTTLPR alleles were
only indirectly linked with alcohol- and marijuana-related prob-
lems at 6-month follow-up in treated youth, through severity of
externalizing behavior. These novel results in a sample of youth
in substance use treatment tentatively suggest that 5-HTTLPR
genotype, which was associated with externalizing behavior, might
provide a possible target for treatment related to serotonergic
functioning and externalizing behavior [see Ref. (48)].
The mixed findings in the literature regarding associations
of low expressing 5-HTTLPR genotypes with externalizing and
substance use phenotypes urge caution in the interpretation of
this study’s results. Although study findings are consistent with
research reporting that low, relative to high, expressing alleles
are associated with externalizing behavior and substance use, and
other studies have found the opposite pattern. For example, low
level of alcohol response in men, which is associated with alco-
hol dependence, was correlated with high expressing 5-HTTLPR
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genotypes (LA homozygotes) (8), suggesting that an association
between the L-allele and alcohol dependence may be specific to
certain subgroups (18), and differ by gender (49). The mixed
findings across studies might reflect differences in sample ascer-
tainment and phenotype definition, and whether co-occurring
psychiatric conditions, and L-allele subtypes and haplotypes were
examined (50).
This study had limitations. The majority of participants were
Caucasian, male, and in substance use treatment (primarily for
cannabis use disorder), which limits generalizability. Sample size
overall was limited. Analyses did not correct for multiple com-
parisons, and results require replication. A comparison group of
adolescents with no substance use problems was not examined.
Measures of more narrowly defined phenotypes (e.g., response
inhibition), which may underlie externalizing behaviors, were not
examined. Haplotype analyses were not done. Only one candi-
date region of the SLC6A4 gene was examined. Ideally, whole
exome sequencing of all genes involved in serotonergic metab-
olism would be conducted to rule out rare variants, which could
bias results by exerting a stronger effect on the phenotype than
HTTLPR length alone.
Youth with low expressing 5-HTTLPR genotype and exter-
nalizing behaviors may benefit from interventions that address
serotonergic functioning [see Ref. (48)], and intensive treatment
that simultaneously aims to reduce externalizing behaviors and
substance use [e.g., Ref. (51)]. However, further research is needed
to more precisely identify relevant treatment targets, and to repli-
cate results. With regard to public health implications, predictive
and diagnostic genetic testing for psychiatric conditions is promis-
ing, yet premature, given mixed findings and relatively small effects
of common genetic variants (52). However, greater understand-
ing of single gene effects, based on multiple methods (e.g., whole
exome sequencing, model systems) and converging results, is crit-
ical to characterizing the pathophysiology of complex diseases,
which could ultimately guide the development of novel treatments
for substance use (6).
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